Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Kiadis Pharma N.V.
  6. News
  7. Summary
    KDS   NL0011323407


End-of-day quote. End-of-day quote Euronext Amsterdam - 05/24
5.46 EUR   +0.18%
05/14KIADIS PHARMA Ná : - Notice of Annual General Meeting of Shareholders
05/13KIADIS PHARMA Ná : AGM QA Protocol
05/13KIADIS PHARMA Ná : AGM Agenda
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Kiadis Pharma N : - Notice of Annual General Meeting of Shareholders

05/14/2021 | 07:26am EDT

Amsterdam, The Netherlands - Kiadis Pharma N.V. ('Kiadis Pharma' or the 'Company') (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, announces that its Annual General Meeting of shareholders ('AGM') will be held at 15:00 CEST on 28 June 2021.

Pursuant to temporary emergency legislation regarding COVID-19 in The Netherlands, the AGM can only be accessed electronically. This means that it will not be possible to attend the AGM in person. Instead, the Company will provide instructions how to connect to the virtual AGM (audio only) to those shareholders that have registered on time for the AGM. Although this will not be interactive, shareholders who have registered will be able to submit written questions, to grant a proxy and issue voting instructions before the AGM.

The notice, agenda and proxy form for the AGM are available on the Investors' section of the Kiadis Pharma website at: http://www.kiadis.com/investors/shareholders-meetings/.

Dutch Translation/Nederlandse vertaling

Amsterdam, Nederland, 13 mei 2021 - Kiadis Pharma N.V. ('Kiadis Pharma' of de 'Vennootschap') (Euronext Amsterdam en Brussel: KDS), een biofarmaceutisch bedrijf in klinische fase, kondigt vandaag aan dat de jaarlijkse Algemene Vergadering van Aandeelhouders ('AVA') wordt gehouden op 28 juni 2021 om 15:00 uur CEST.

Conform de tijdelijke noodwetgeving met betrekking tot COVID-19 in Nederland is de AVA alleen elektronisch toegankelijk. Dit betekent dat het niet mogelijk zal zijn om de AVA in persoon bij te wonen. In plaats daarvan zal de Vennootschap de aandeelhouders die zich op tijd voor de AVA hebben aangemeld, instructies geven over hoe zij verbinding kunnen maken met de virtuele AVA (alleen audio). Hoewel dit niet interactief zal zijn, zullen de aldus aangemelde aandeelhouders voor de AVA schriftelijke vragen kunnen stellen en een volmacht en steminstructies kunnen geven.

De aankondiging, agenda voor de AVA en het volmacht formulier zijn beschikbaar op de Investors sectie de Kiadis Pharma website op: http://www.kiadis.com/investors/shareholders-meetings/.

De bovenstaande tekst is een vertaling van de Engelstalige oproeping voor de AVA. Bij eventuele verschillen is de tekst van de Engelstalige oproeping altijd leidend.

About Kiadis

Founded in 1997, Kiadis is committed to developing innovative cell-based medicines for patients with life-threatening diseases. With headquarters in Amsterdam, The Netherlands, and offices and activities across the United States, Kiadis is reimagining medicine by leveraging the natural strengths of humanity and our collective immune system to source the best cells for life. Following a successful public offer, Sanofi and Kiadis have now joined forces to expand and accelerate the potential benefits of novel cell-based therapies to treat cancer patients.

Kiadis is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at www.kiadis.com. As announced by Kiadis on 26 April 2021 (https://ir.kiadis.com/news-releases/news-release-details/delisting-kiadis-will-be-effective-25-may-2021), the delisting of the Company's shares from Euronext Amsterdam and Euronext Brussels will be effective as of 25 May 2021.



Maryann Cimino


Investor Relations & Corporate Affairs

Tel: +1 617 710-7305

M: cimino@kiadis.com


LifeSpring Life Sciences Communication

Leon Melens


Tel: +31 6 538 16 427

E: lmelens@lifespring.nl

Optimum Strategic Communications

Mary Clark

Supriya Mathur

Tel: +44 203 950 9144

E: kiadis@optimumcomms.com

Kiadis Forward-Looking Statement

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis' or, as appropriate, Kiadis' officers' current expectations and projections about future events. By their nature, forward-looking statements involve a number of known and unknown risks, uncertainties and assumptions that could cause actual results, performance, achievements or events to differ materially from those expressed, anticipated or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance, achievements or results to differ significantly from any anticipated or implied development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or projections, or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the anticipated or implied developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.



301 Edgewater Place - Suite 100

Wakefield, MA 01880

Phone: 978.921.4125

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about KIADIS PHARMA N.V.
05/14KIADIS PHARMA Ná : - Notice of Annual General Meeting of Shareholders
05/13KIADIS PHARMA Ná : AGM QA Protocol
05/13KIADIS PHARMA Ná : AGM Agenda
04/29SANOFIá : to Delist Kiadis in Amsterdam, Brussels on May 25
04/29FINAL RESULTS OF THE OFFER FOR KIADI : 97.39% of Kiadis Shares in total committe..
04/29KIADIS PHARMA N.V.á : Annual results
04/26SANOFIá : to Delist Kiadis from Euronext on May 25
04/19SANOFIá : completes Kiadis acquisition
04/18SANOFIá : Closes $368 Million Purchase of Kiadis
More news
Sales 2020 17,5  21,2  21,2 
Net income 2020 -81,9 M -99,3 M -99,3 M
Net Debt 2020 0,65 M 0,79 M 0,79 M
P/E ratio 2020 -2,35x
Yield 2020 -
Capitalization 334 M 408 M 404 M
EV / Sales 2019 -
EV / Sales 2020 12 187 162x
Nbr of Employees 103
Free-Float 2,78%
Duration : Period :
Kiadis Pharma N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Arthur K. Lahr Chief Executive Officer
Paul van Hagen Senior Vice President-Finance
Mark A. Wegter Chairman-Supervisory Board
Andrew S. Sandler Chief Medical Officer
Robert Friesen Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.109.49%87 874
LONZA GROUP AG16.32%54 656
CELLTRION, INC.-26.04%32 458
SEAGEN INC.-10.60%28 416